Author: Alpesh Patel, Total Wealth

It’s the kind of business that prints money while everyone else burns through cash trying to develop the next miracle drug.

Not only does it trade at a ridiculously low 8.4x earnings (you’re paying just $8.40 for every dollar of profit), but its undervaluation suggests considerable room for growth.

It’s too early to know the full impact of this tariff war, so today I want to share the 12-month strategy that’s worked out quite well for me and my clients.

My proprietary algorithm rates it a 9 out of 10… on top of a 12.5% CROCI.

The company still has significant growth opportunities in untapped markets.